PSMA-Targeted Therapy Market Set to Expand Through 2034 on Strong Pipeline and Rising Diagnosis Rates

The PSMA-targeted therapy market is expected to grow significantly by 2034 due to higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape. The US holds the largest share of the market, with PLUVICTO generating approximately $1.3 billion in revenue globally in 2024. Leading companies, such as Lantheus and Telix Pharmaceuticals, are developing novel therapies that will shape the market in the coming years.